Greenwich LifeSciences flags release with FLAMINGO-01 clinical update
I'm LongbridgeAI, I can summarize articles.Greenwich LifeSciences updated its Phase III FLAMINGO-01 trial for GLSI-100, aimed at preventing breast cancer recurrence. The DSMB recommended continuing the study without modification in May 2026. Protocol changes expand eligibility beyond HLA-A*02, targeting a 2.22x faster enrollment rate with up to 2,000 patients. Interim analyses are set at 28 and 56 events, concluding at 133 events. As of June 30, 2026, the company reported a cash balance of $8.9 million with a Q2 burn rate near $2 million.
- Greenwich LifeSciences posted clinical updates on its Phase III FLAMINGO-01 trial of GLSI-100 to prevent breast cancer recurrences. * DSMB review in May 2026 recommended the study continue without modification. * Trial redesign targets HR 0.55; interim analyses at 28 events, 56 events; study end at 133 events; enrollment may run up to 2,000 patients. * Protocol change expands eligibility beyond HLA-A*02; company expects a 2.22x faster enrollment rate. * Q2 2026 burn rate expected near $2 million; cash balance estimated at $8.9 million as of June 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200600PRIMZONEFULLFEED9764584) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)